Evidence map›Paper›PMID 41039440›Full record

SynthesisBMC pulmonary medicine2025

Risk factors for bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation: a systematic review and meta-analysis.

Guangchen Pu, Guangmin Nong, Qing Wei, Yunyan He, Wenguang Jia, Zhenhao Lu, Guosheng Qiu, Jun Xie, Xun Chen

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Guangchen PuDifficult and Critical illness Center, Pediatric Clinical Medical Research Center of Guangxi, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, China.
Guangmin NongDifficult and Critical illness Center, Pediatric Clinical Medical Research Center of Guangxi, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, China.
Qing WeiDifficult and Critical illness Center, Pediatric Clinical Medical Research Center of Guangxi, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, China.
Yunyan HeDifficult and Critical illness Center, Pediatric Clinical Medical Research Center of Guangxi, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, China.
Wenguang JiaDifficult and Critical illness Center, Pediatric Clinical Medical Research Center of Guangxi, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, China.
Zhenhao LuDifficult and Critical illness Center, Pediatric Clinical Medical Research Center of Guangxi, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, China.
Guosheng QiuDifficult and Critical illness Center, Pediatric Clinical Medical Research Center of Guangxi, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, China.
Jun XieDifficult and Critical illness Center, Pediatric Clinical Medical Research Center of Guangxi, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, China.
Xun ChenDifficult and Critical illness Center, Pediatric Clinical Medical Research Center of Guangxi, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, China. chenxun1227@163.com.

Funding

Guangxi Clinical Research Center for Pediatric disease NO:AD22035219Natural Science Foundation of Guangxi Province 2023GXNSFAA026134
6 · The paper itself

Abstract

backgroundBronchiolitis obliterans syndrome (BOS) after hematopoietic stem cell transplantation (HSCT) is a late-onset complication that significantly impairs patients' quality of life and is associated with a high mortality rate. Currently, the risk factors for BOS after HSCT remain controversial. We therefore conducted a systematic review and meta-analysis to identify potential risk factors associated with BOS after HSCT.

methodsThree primary medical databases (PubMed, Web of Science, Embase) were exhaustively reviewed from their inception through November 2024 to assess contributing factors for BOS occurrence following HSCT. Data synthesis was conducted using RevMan 5.4 for meta-analytic evaluation.

resultsFourteen studies involving 10,317 HSCT recipients were included, 778 of whom developed BOS. Female sex (OR = 1.26; 95% CI: 1.08, 1.47; p = 0.003), ABO blood group incompatibility (OR = 1.39; 95% CI: 1.07, 1.81; p = 0.01), peripheral blood stem cell transplantation (PBSCT) (OR = 1.31; 95% CI: 1.04, 1.64; p = 0.02), myeloablative conditioning (MAC) (OR = 1.63; 95% CI: 1.23, 2.16; p = 0.0008), acute graft-versus-host disease (aGVHD) (OR = 1.93; 95% CI: 1.16, 3.23; p = 0.01), grade Ⅱ-Ⅳ aGVHD (OR = 1.41; 95% CI: 1.12, 1.77; p = 0.004), and extrapulmonary chronic graft-versus-host disease (cGVHD) (OR = 11.69; 95% CI: 5.29, 25.82; p < 0.00001) were associated with an increased risk of BOS after HSCT.

conclusionsFemale sex, ABO blood group incompatibility, PBSCT, MAC, aGVHD (especially grade II-IV), and extrapulmonary cGVHD are associated with an increased risk of BOS after HSCT. PROSPERO REGISTRATION: CRD42024609569.

Indexed as

Bronchiolitis ObliteransHematopoietic Stem Cell TransplantationBronchiolitis Obliterans SyndromeFemaleGraft vs Host DiseaseHumansMaleRisk FactorsSex FactorsTransplantation ConditioningBronchiolitis obliterans syndromeHematopoietic stem cell transplantationMeta-analysisRisk factor

Identifiers

PMID41039440
PMCPMC12492564

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.